GS1 Australia

The Global Language of Business

# Healthcare NPC Advisory Group

## (HCNPCAG)

## 3Q 2020 meeting

26th August 2020

# Welcome, introductions and apologies

# Healthcare NPC Advisory Group
# **Agenda**

| Time | Subject | Who |
|---|---|---|
| 2:00pm | Welcome, introductions and apologies | CO-CHAIR |
| 2:15pm | GS1 Australia Limited Trade Practices Compliance Notice | CO-CHAIR |
| 2:20pm | Approve previous minutes from 2Q 2020 meeting (17 June 2020) | ALL |
| 2:25pm | Review of Action Items – per update in previous minutes | ALL |
| 2:35pm | Regular updates | ALL |
| 3.00pm | New Topics - Healthcare Dataset Review | ALL |
| 3.45pm | Any other business/topics | ALL |
| 3:50pm | Confirmation of actions and next steps | CO-CHAIR |
| 3:55pm | Confirm next meeting, Thanks, and meeting close | CO-CHAIR |

# Trade Practices Compliance Notice

# GS1 Australia Trade Practice Compliance Notice

Participants on GS1 Boards, committees, task forces, work groups, or other similar bodies, must always remember the purpose of the Board, committee, task force, or work group is to enhance the ability of all industry members to compete more efficiently and effectively to provide better value to the consumer or end user. GS1 activity almost always involves the cooperation of competitors; therefore great care must be taken to assure compliance with trade practices laws in Australia and in other jurisdictions

**This means:**

- Participation must be voluntary.
- There will no exchange of confidential information such as prices products.
- Meetings will have a pre-prepared agenda and recorded by minutes.
- All recommendations from any meeting are recommendations only. Individual companies remain free to make independent, competitive decisions.
- Any standards developed must be voluntary standards.
- If any participant believes the group is drifting toward impermissible discussion, the topic shall be tabled until the opinion of lawyer(s) with experience in trade practices law can be obtained.

# Approve previous minutes

2Q meeting (17th June 2020)

# Review of Actions Log

Refer to Minutes (17th June 2020)

# Actions Log

| | Action Items | Owner | Deadline | Status |
|---|---|---|---|---|
| 1.1 | Terms of Reference to be updated with feedback from Kick Off meeting & distributed to HCNPCAG members for review and approval at commencement of Meeting 1 2020. | Gary Russon (GS1)/ALL | Closed | Approved, Item closed 19 February 2020 |
| 1.2 | Call for Co-Chair Nominations from HCNPCAG group members in accordance with Terms of Reference. | Gary Russon (GS1)/ALL | Closed | Rob Setina (HPV) and Elizabeth Donohoo (ADHA) confirmed as co-chairs 17th June 2020 |
| 1.3 | Detailed NPC statistics to be provided for reference at all future HCNPCAG meetings | Sascha Timoshanko (GS1) | Closed | This is to be closed as an action item and be included as part of the standing agenda for the AG meetings |
| 1.4 | Healthcare Data set & Use Case Review by industry | Cath Koetz & Murray Robb (GS1) | Launch 26th August | Discussion at meeting on 26th August to launch after delays. |
| 1.5 | Enhancement requests for NPC platform and Data Quality Improvement reports | Justin Middleton & Murray Robb (GS1)/All | Closed | This will be closed as an action and be included as a part of the standing agenda of the AG meetings |
| 1.6 | Nominations for additional industry representation (in line with Terms of Reference) | GS1/ALL | Closed | Additional nominations open at any time. This will be closed as an action and be included as a part of the standing agenda of the AG meetings |
| 1.7 | Meeting requests including Zoom dial in details to be sent to HCNPCAG group members for all 2020 meetings | GS1 | closed | 2020 meetings have all been set and invitations sent. |
| 2.1 | *Executive level 'Value proposition'*<br>Document for use within suppliers providing 'talking points' to assist with understanding the value of the NPC | Mark Blitenthall /Marian Makram Perkins/Cath Koetz (GS1) | 01/05/2020 | Overdue<br>Draft to be provided to AG members for review and comment. |
| 2.2 | Recipients to share details of their programs on an ongoing basis to the AG (within Recipient updates) | Recipients (ALL) | Closed | This will be closed as an action and be included as a part of the standing agenda of the AG meetings |
| 2.3 | Further discussion in future meetings to ensure that required NPC statistics are available across all active Recipients to further detail the utilisation of NPC data. | GS1 staff<br>Recipients (ALL) | closed | No additional feedback provided, closing item as an action and can revisit in future as needed |
| 3.1 | GHS (Global Harmonised System) as possible NPC attribute for Dangerous & Hazardous Goods classification and reporting | AG members to advise within dataset review | Open | |
| 3.2 | Creation of ADHA driven AMT-CTPP – GTIN paper, outlining data linkage initiative and industry support. Also call for ideas supporting other digital or meds management initiatives/policies, calls for ideas – note. | Pan Teng (ADHA)<br>Cath Koetz/Murray Robb (GS1) | Open | Pan to seek assistance to craft statement on AMT-CTPP – GTIN initiative.<br>Cath & Murray to look at mechanisms to support process from GS1 side |
| 3.3 | Understanding UNSPSC selection process for suppliers, specifically any barriers in fulfilling populating current code set values for products and publishing to NPC. | Cath Koetz/Murray Robb (GS1) & Rob Setina (HPV) | Open | GS1 to investigate UNSPSC selection issues and revert to group with more info to support further discussion and any further investigation. |

# Regular Updates

- NPC statistics – detailed update on # of users and product records
- Data Quality Improvement progress
- AMT CTPP/GTIN project update
- Updates from Recipients on their programs

# GDSN Statistics – end July 2020

**65,372 GLN/entities involved**

incl manufacturers/suppliers, recipients (health organisations, GPO, distributors etc..), government agencies etc..

**38 Active GDSN Datapools working in healthcare**

Australia's NPC is 3rd largest globally

**133 Countries (Target Markets)**

**4,004,456 Product Records**

- 3,245,252 MedTech
- 77,967 Pharma
- 681,237 Other

https://www.gs1.org/services/gdsn/statistics

# NPC HC Statistics – AU (July 2020)

**624 Publishers/Suppliers**
(+18, since 1st Jan 2020)

**5 Certified Product Providers**

**22 Recipients**
- 8 state health departments
- 3 private hospital groups
- 10 distributors
- ADHA

**466,329 Product Records**
(+6.7%, since 1st Jan 2020)
- 343,089 MedTech
- 123,240 Pharma & Other

# Healthcare Data Quality Program










| | Red | Bronze | Silver | Gold | Platinum |
|---|---|---|---|---|---|
| Aug 2020 | 96 – 22% | 33 – 7% | 26 – 6% | 24 – 5% | **262 – 59%** |
| May 2020 | 110 – 25% | 32 – 7% | 21 – 5% | 25 – 6% | **259 – 58%** |
| Feb 2020 | 98 – 25% | 26 – 7% | 15 – 4% | 20 – 5% | **238 – 60%** |

| | Top 5 DQ Errors |
|---|---|
| 1 | Missing Manufacturer Name |
| 2 | Missing v19.0501 UNSPSC code |
| 3 | Invalid values for depth |
| 4 | Invalid values for width |
| 5 | Invalid values for height |

# Regular Updates

## AMT CTPP/GTIN project update

# Regular Updates

Updates from Recipients on their programs

# New Topics

- Healthcare Dataset Review 2020

# Data Set Review

## Background:

- Agreement with industry to conduct a complete review every three years
- Last healthcare data set review 2017

## Who/What is involved:

- All stakeholders who use, review or plan to use the NPC can participate
- Detailed review of the requirements by the sector
- Planning for roll out incl communication and training if needed

## Data Set Review Objectives:

- Attributes – required / not required
- Business requirements – validation rules
- Make it easier & more valuable to implement

# Data Set Review – Current versus Future

## Current state:

- Two data set groupings, 'Healthcare AU' and 'Pharmacy Wholesale' with no easy way to differentiate data requirements by product type

## Proposed approach:

- Create a more targeted data set with 'Medical Devices' and 'Pharmaceuticals' datasets that reflect the specific product groups and data needs where possible
- Reduce the use of 'R' (required if applicable) flags
- Clarify & possibly reduce the total number of attributes per product group

| **Medical Devices** | | | | **Pharmaceuticals** | | |
|---|---|---|---|---|---|---|
| Consumables | Implants | Assets | InVitro Diagnostics | Ethical | Consumer | Complimentary |

## Out of scope:

- Food Service/Catering and General consumables/merchandise (stationery, cleaning etc..)
- Pricing – as the price message is a standard message but requirements are recipient defined

# Dataset Review – Considerations and Stakeholders

| Some of the Key Stakeholders | Some Considerations |
|---|---|
| Procurement organisations | Supply chain requirements |
| Supply Chain functions | Prosthesis Rebate/PBS/RPBS |
| eHealth and Health Informatics | Theatre management solutions |
| Hospital procurement/purchasing | IVD |
| Clinical systems/people | Large Assets/Multi-component Medical devices |
| Pharmacy | MRI compatibility |
| Theatres | Access to manual |
| Oncology | Future UDI requirements? |
| Biomedical engineering | Special Access Scheme products |
| Angio/Interventional radiology | AMT CTPP (linkage to clinical terminology) |
| Pathology | Allergens |
| Administration/Finance | Routes of Administration |
| Patient (record) | Dose/Form etc |
| Registries | Linkages to additional information - consumer medicines information |
| Manufacturers/Distributors | (CMI) or Instructions for Use (IFU) or Consumer Fact Sheet (Patient |
| Dept Health – Digital, Regulation, Funding, NCTS | Card) or Safety sheets (MSDS) etc.. |
| Pharmacies/Pharmacists | Classification codes/Categories of product |
| MIMS/NPS | Countries of origin |
| | Descriptions |
| | Need versus Nice to have |

# Dataset – based on needs

| | Medical devices | Pharmaceuticals |
|---|---|---|
| Core Item Master | • Description(s)<br>• Supplier part Number<br>• Manufacturer part number<br>• Unique product ID<br>• Manufacturer Name<br>• Net content<br>• Units of Measure<br>• Product Hierarchy (Carton/Box/Pack/Unit of use) | • Description(s)<br>• Generic Name<br>• Supplier part Number<br>• Manufacturer part number<br>• Unique product ID<br>• Manufacturer name<br>• Net content<br>• Units of Measure<br>• Product Hierarchy (Carton/Bundle/Pack/Unit of use)<br>• Dose<br>• Strength<br>• Dose Form |
| Additional Item Master | • Brand<br>• Variant<br>• Colour<br>• Size<br>• Functional equivalent (from same manufacturer)<br>• Replacement product (in case of update)<br>• Origin of product | • Brand<br>• Variant<br>• Colour<br>• Functional equivalent (from same manufacturer)<br>• Replacement product (in case of update)<br>• Price on Pack<br>• Date on pack<br>• Narcotic Drug Number<br>• Pack Label description<br>• PBS<br>• Origin of product |

examples

# Dataset – based on needs

| | Medical devices | Pharmaceuticals |
|---|---|---|
| Purchasing | • Ordering Unit<br>• Order lead time<br>• Order unit multiples<br>• Invoicing unit<br>• Tax rate/exemption | • Ordering Unit<br>• Order lead time<br>• Order unit multiples<br>• Invoicing unit<br>• Tax rate/exemption |
| Supply chain/Logistics | • Weights<br>• Dimensions<br>• Dangerous Goods information<br>• Handling information<br>• Conversion information (Carton/Box/Pack/Unit of Use)<br>• Sterilisation/Sterile Pack<br>• Returnable packaging<br>• Contents within a kit/pack<br>• Standard Pallet information<br>• Storage requirements<br>• Instructions for use<br>• Materials Safety data sheets | • Weights<br>• Dimensions<br>• Dangerous Goods information<br>• Handling information<br>• Conversion information (Carton/Bundle/Pack/Unit of Use)<br>• Storage temp/Cold chain requirements<br>• Contents within a pack (eg: a Liquid + Powder, 24 x Tablets, Box of doses etc.. )<br>• Standard Pallet information<br>• Consumer Medicines Information<br>• Physician Information<br>• Materials Safety data sheets |
| Reimbursement/ Funding/Finance | • Prothesis Rebate Code<br>• Categorisation | • PBS<br>• RPBS<br>• Categorisation |
| Certifications/Approvals | • ARTG<br>• CE Mark | • ARTG |

# Dataset – based on needs

| | Medical devices | Pharmaceuticals |
|---|---|---|
| Clinical Use/ Patient record/Registries | • Product used/implanted<br>• Instructions for use (IFU)<br>• Patient information<br>• MRI compatibility<br>• Product family | • Product used/given<br>• AMT Linkage<br>• Routes of Administration (approved)<br>• Consumer Medicines Information/Physician Information<br>• Form/Dose/Strength<br>• Generic Product name |
| Reporting | • Internal<br>• Regulator/Other agencies<br>• Origin of product<br>• Dangerous Goods | • Internal<br>• Regulator/Other agencies<br>• Dangerous Goods |
| Categorisation & Classification | • UNSPSC<br>• GMDN<br>• Risk Classification | • UNSPSC<br>• Schedule classification<br>• |
| Packaging | • Packaging information for recyclability/disposal<br>• Details needed for sustainability reporting<br>• DEHP | • Packaging information for recyclability/disposal<br>• Details needed for sustainability reporting<br>• DEHP |
| Safety | • MRI compatibility<br>• Latex<br>• Flash point<br>• Storage instructions<br>• Preparation before use (eg: sterilisation required) | • Cytotoxicity<br>• Dangerous/Hazardous<br>• Preparation information (eg: mixing required)<br>• Flash point<br>• Storage instructions |

examples

# Dataset Review – Recipients

## Objective:

- Ensure that the NPC data set supports your organisation wide requirements for sourcing product related item master data across all relevant use cases
  - Remember the NPC was designed to ensure consistent and validated data is used in how you manage products across your organisations
  - 'Creation' of data by other means immediately introduces duplication of effort, introduces differences in the data across your organisation and can introduce risk if data is not validated

## Process:

- Engage with the experts in your organisation as needed to fill gaps if the process is being led by procurement – Clinical system leads (Pharmacy and Theatre), Health Informatics and eHealth teams, BioMed, Finance/Reimbursement, Supply chain/Operations, Quality & Risk, etc..
- Review requirements for product based data across organisation & systems
- Use the opportunity to gain a better understanding of where gaps are in architecting data from NPC to systems that are managing product today (or need to in the future) - please include feedback related to your challenges to access the data in section provided

# Dataset Review – Suppliers

## Objective:

- Ensure that the NPC data set supports your organisation wide requirements for providing product related item master data
  - Remember the NPC was designed to provide a single mechanism of provide data to all trading partners for all their data needs so capturing all the (regular) adhoc requests is important in addition to the official regular requests
  - Your product data is key to ensuring that your products are able to be ordered, transported/managed/stored, transformed (when sold in cartons but sent to sites as individual units), used on/by clinicians/patients, reimbursed/funded, recorded in patient records, reported on, etc..

## Process:

- Engage with the internal departments as needed to fill gaps – Commercial, Data Management, Finance, Supply chain, Customer Service, Regulator Affairs etc..
- Use the opportunity to gain a better understanding of where data requests are being sent from recipients who are on NPC (or their affiliate organisations) – tell us your challenges re providing the data in section provided

# Dataset Review – Additional considerations

For group feedback to ensure we add to scope/acknowledge out of scope:

- Do you want use to host detailed reviews to run through? As a group or as organisations?
-
-
-

# Dataset Review – Next steps

- AG to agree to proposed timeframe
  - Completion of feedback by participants (4 weeks)
  - GS1 to query consolidate feedback & clarify as needed (2 weeks)
  - Results to participants for review & provide feedback (1 week)
  - GS1 to update consolidated feedback (1 week)
  - Meeting with participants (special meeting) to review and ensure consensus (21 October 2020)
  - Final for sign off at Q4 AG meeting 11 November 2020
  - Communicate results and any changes to sector/wider stakeholders
  - Transition into BAU
- GS1 will send packs to all AG organisations & other participant organisations
- Participants to Opt-in/Opt-out of the process
- GS1 to support participants as needed

# Any other business/Topics

# Confirmation of actions and next steps

# Confirm next meeting dates

**Data set review** – proposed for 21 October 2020 (TBC)
**4Q 2020** - Wed 11/11/2020, 2-4pm

# Meeting close